Checkpoint Therapeutics Stock (NASDAQ: CKPT) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 500.149K |
Day Range | - - - |
52 Wk Range | 1.300 - 3.620 |
Market Cap | $54.243M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 30 |
Short Interest | 11.59% |
Days to Cover | 9.64 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Checkpoint Therapeutics (NASDAQ: CKPT) through any online brokerage.
Other companies in Checkpoint Therapeutics’s space includes: Kezar Life Sciences (NASDAQ:KZR), Gain Therapeutics (NASDAQ:GANX), Intensity Therapeutics (NASDAQ:INTS), Eagle Pharmaceuticals (NASDAQ:EGRX) and Immuneering (NASDAQ:IMRX).
The latest price target for Checkpoint Therapeutics (NASDAQ: CKPT) was reported by HC Wainwright & Co. on Friday, March 22, 2024. The analyst firm set a price target for 34.00 expecting CKPT to rise to within 12 months (a possible 2136.84% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Checkpoint Therapeutics (NASDAQ: CKPT) is $1.52 last updated April 22, 2024 at 5:42 PM EDT.
There are no upcoming dividends for Checkpoint Therapeutics.
Checkpoint Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Checkpoint Therapeutics.
Checkpoint Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.